May 1, 2020 / 9:59 PM / a month ago

BRIEF-Revance And Mylan Biosimilar To Botox Program Decision To Extend Beyond April 30, 2020

May 1 (Reuters) - Revance Therapeutics Inc:

* REVANCE AND MYLAN BIOSIMILAR TO BOTOX® PROGRAM DECISION TO EXTEND BEYOND APRIL 30, 2020

* REVANCE THERAPEUTICS - CONTINUING DISCUSSIONS WITH MYLAN N.V. REGARDING WHETHER OR NOT MYLAN PLANS TO MOVE FORWARD WITH BIOSIMILAR TO BOTOX PROGRAM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below